Published on: May 14, 2015 at Dana Farber Cancer Institute

New drug combination boosts survival in advanced stomach and esophageal cancers

By : Dana Farber Cancer Institute

Patients whose metastatic stomach or esophageal cancers were driven by a mutatedHER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination.

Read More
SHARE